Replimune's drug for advanced skin cancer fails to win FDA nod again - Reuters
Replimune's drug for advanced skin cancer fails to win FDA nod again Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQV0xhbE5EbkRDa2l2OEdTdkhHRzlZU1cwdUM4bWt6ZGVTTWNIeFFUdHhDaW9SOHBiM3A3eV9VVTZoNXlRM0pNSk5adXJ1Vkw1SDZqSWI5aGlfT3B1VThsV21acFBVUU1RTE9oZXNSbHRMUlZTSzhNTGdXQTJELUgycm1QM0d5cGdQdlNicURjZEZ5LXVxa2t6MWh0aEI2N1o0UVM1X2VxMDAtb0t1T0pzSFdNTQ?oc=5" target="_blank">Replimune's drug for advanced skin cancer fails to win FDA nod again</a> <font color="#6f6f6f">Reuters</font>
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
Similar Stories
Related coverage based on topic and tags
GSK's Jemperli meets main goal in mid-stage rectal cancer trial - Reuters
GSK's Jemperli meets main goal in mid-stage rectal cancer trial Reuters
July 13, 2026 at 06:45 PMUS FDA approves Celcuity's breast cancer drug - Reuters
US FDA approves Celcuity's breast cancer drug Reuters
July 14, 2026 at 10:36 PMGSK, Hansoh's targeted cancer drug hits main survival goal in China trial - Reuters
GSK, Hansoh's targeted cancer drug hits main survival goal in China trial Reuters
July 10, 2026 at 01:46 PMUS FDA approves Sanofi's wearable injector form of blood cancer drug - Reuters
US FDA approves Sanofi's wearable injector form of blood cancer drug Reuters
July 10, 2026 at 05:49 PMUS FDA approves Vera's kidney disease drug - Reuters
US FDA approves Vera's kidney disease drug Reuters
July 7, 2026 at 05:09 PMAstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports - Reuters
AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports Reuters
July 8, 2026 at 06:34 PM